Predictive Biomarkers and Personalized Medicine

Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu1, Andrea Sartore-Bianchi1, Catia Moutinho5, Alessandro Belotti1, Katia Bencardino1, Giuseppe Chirico2, Andrea Cassingena1, Francesca Rusconi1, Anna Esposito3, Michele Nichelatti4, Manel Esteller5,6,7, and Salvatore Siena1

Abstract

Purpose: O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein removing mutagenic and cytotoxic adducts from O6-guanine in DNA. Approximately 40% of colorectal cancers (CRC) display MGMT deficiency due to the promoter hypermethylation leading to silencing of the gene. Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O6-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT. We conducted a phase II study with dacarbazine in CRCs who had failed standard therapies (oxaliplatin, irinotecan, fluoropyrimidines, and cetuximab or panitumumab if KRAS wild-type).

Experimental Design: All patients had tumor tissue assessed for MGMT as promoter hypermethylation in double-blind for treatment outcome. Patients received dacarbazine 250 mg/m² intravenously every day for four consecutive days, every 21 days, until progressive disease or intolerable toxicity. We used a Simon two-stage design to determine whether the overall response rate would be 10% or more. Secondary endpoints included association of response, progression-free survival, and disease control rate with MGMT status.

Results: Sixty-eight patients were enrolled from May 2011 to March 2012. Patients received a median of three cycles of dacarbazine (range 1–12). Grades 3 and 4 toxicities included: fatigue (41%), nausea/vomiting (29%), constipation (25%), platelet count decrease (19%), and anemia (18%). Overall, two patients (3%) achieved partial response and eight patients (12%) had stable disease. Disease control rate (partial response + stable disease) was significantly associated with MGMT promoter hypermethylation in the corresponding tumors.

Conclusion: Objective clinical responses to dacarbazine in patients with metastatic CRC are confined to those tumors harboring epigenetic inactivation of the DNA repair enzyme MGMT. Clin Cancer Res; 19(8); 2265–72. ©2013 AACR.

Introduction

Globally, nearly 1.25 million patients are diagnosed and more than 600,000 patients die from colorectal cancer (CRC) each year (2008 estimates; ref. 1). At least 50% of patients develop metastases (2), and most of these patients have unresectable tumors (2, 3).

In the last 10 years, thanks to a wider clinical use of a multidisciplinary approach, along with the introduction of new cytotoxic drugs and the addition of targeted therapies against the angiogenesis (bevacizumab and aflibercept), the EGF receptor (EGFR) pathway (cetuximab and panitumumab), or multiple receptor tyrosine kinases (regorafenib), the survival of patients with metastatic CRC (mCRC) has considerably been ameliorated (4–6). Nevertheless, prognosis remains poor and patients carrying KRAS mutations (35%–40% of CRCs), which preclude responsiveness to cetuximab or panitumumab (6), have limited therapeutic options after failure of 2 lines of standard treatments, although a significant percentage of these patients retain a good performance status potentially allowing further therapies. There is therefore an unmet need of therapeutic...
**Translational Relevance**

O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Approximately 40% of colorectal cancers (CRC) display MGMT deficiency due to promoter hypermethylation leading to silencing of the gene. Alkylation agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O6-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT. Although several reports have shown anecdotal efficacy of dacarbazine in metastatic CRC, there is a lack of translational evidence of CRC sensitivity to this drug based on MGMT status. We report here a phase II clinical study showing for the first time that dacarbazine activity is confined to CRC harboring promoter CpG hypermethylation of MGMT. These data therefore highlight a previously unidentified subgroup of the patients with CRC who benefit from treatment with alkylating agents based on a specific epigenetic alteration in individual tumors.

In cells, loss of MGMT expression leads to compromised DNA repair and may play a significant role in cancer progression and response to chemotherapy as it occurs in glioma (13–16). The mechanism of action of dacarbazine and temozolomide is DNA methylation at the O6-guanine site, inducing base pair mismatch. The methyl group at O6-site is removed by MGMT in a one-step methyl transfer reaction. Therefore, we hypothesized that MGMT inactivation by hypermethylation may confer sensitivity to these agents (17). However, discrepant data about the clinical activity of these drugs in mCRC are reported in the literature (18–21). A response rate of 19%, including one complete response, was reported in 26 fluoropyrimidine-resistant patients receiving cisplatin and dacarbazine (19). In another study, 48 patients refractory to fluoropyrimidine were treated with dacarbazine, irinotecan, and cisplatin obtaining a 33% of response rate (18). Temozolomide is an imidazotetrazine derivative of dacarbazine. The combination of lomustine and temozolomide did not show activity in unselected mCRC (20). In a pilot study including patients selected by tumor molecular profiling, temozolomide was effective in 2 patients with mCRC exhibiting loss of MGMT expression (22). The latter finding was confirmed by a recent report by Shacham-Shmueli and colleagues (23) documenting objective responses to temozolomide in 2 patients with MGMT-deficient mCRC.

On the basis of these findings, we designed a phase II trial aimed to assessing the antitumor activity of dacarbazine in patients with mCRC with determined MGMT promoter methylation status and refractory to the standard therapies.

**Materials and Methods**

**Trial design**

The study was designed as a phase II trial (DETECT-01 trial, EUDRACT number 2011-002080-21). Patients were treated with dacarbazine monotherapy until progression or unacceptable toxicity for 18 weeks (6 cycles). In case of partial response with clinical benefit, treatment was allowed until dose-limiting toxicity. Primary endpoint was to assess response rate to dacarbazine according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. Secondary endpoints were to assess: disease control rate (DCR), progression-free survival (PFS), identification of KRAS, and O6-methylguanine-DNA-methyltransferase (MGMT) status in individual tumor samples as potential molecular biomarkers of response to dacarbazine. Written informed consent was obtained from each patient. The study followed the Declaration of Helsinki and good clinical practice, being approved by Ethic Committee of Ospedale Niguarda Ca’ Granda (Milan, Italy).

**Patients**

All patients met the following inclusion criteria: age 18 years or more, Eastern Cooperative Oncology Group performance status of ≤ 1, histologically confirmed metastatic colorectal adenocarcinoma. A paraffin-embedded
block from archival tumor tissue of primary and/or metastases for MGMT status analysis was requested. All patients had measurable disease (by RECIST criteria v1.1), and progressed on standard treatment with fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab or panitumumab (the latter 2 drugs if KRAS wild-type). An adequate bone marrow, liver, and renal function was required.

**Treatment schedules**

Dacarbazine 250 mg/m² intravenously everyday for 4 consecutive days, every 21 days, was administered until progression, death, unacceptable toxicity, or patient withdrawal of consent. Antiemetic agents and supportive care were provided by treating physician as per standard clinical practice. In case of G3 hematologic toxicity (absolute neutrophil count < 1.5 x 10⁹/L and platelet count < 100 x 10⁹/L) dacarbazine was delayed by 1-week interval until recovery. Prophylactic use of colony-stimulating factors was allowed as per standard clinical practice.

**Evaluation criteria**

Patients were evaluated for primary overall response rate (ORR) and secondary endpoint (DCR and PFS) according to RECIST criteria v1.1. Tumors were measured every 8 ± 1 weeks through week 18 and then every 8 ± 1 weeks until the tumor progressed. Complete response was defined as disappearance of all target lesions. Any pathologic lymph nodes (whether target or nontarget) must have reduction in short axis to 10 mm or less. An objective response (partial response) was defined as a reduction of at least 30 percent in the sum of diameters of target lesions, the response nor sufficient increase to qualify for progressive disease, while on study. Clinical investigators and radiologists were blinded as for MGMT status of the tumors.

**Safety assessment**

Safety assessments and blood biochemistry including complete blood counts were carried out at baseline and at the beginning of each treatment cycle. Any toxicity was assessed using the National Cancer Institute (NCI)-CTCAE version 4.0 and recorded at every visit until resolved.

**Analysis of MGMT promoter methylation status**

Loss of expression of MGMT was defined as promoter hypermethylation 25% or more as previously described (9). Tumor samples from patients’ primary tumor were obtained from Pathology Department of the Ospedale Niguarda Ca’ Granda or others Pathology Departments as referral. Formalin-fixed paraffin-embedded tumor blocks were reviewed for quality and tumor content. A single representative block, from either the primary tumor or metastasis, depending on availability, was selected for each case. White slides (2 cut of 10 μm, if from a tumor tissue paraffin block, or 3 cuts of 10 μm if from a biopsy) were sent to Bellvitge Biomedical Research Institute (IDIBELL; Barcelona, Spain) for DNA extraction and evaluation of MGMT promoter methylation status in blind as for clinical outcome. Genomic DNA was extracted from paraffin tissue samples following manufacturer’s instructions (QiAamp DNA FFPE Tissue Kit). DNA was then subjected to bisulfate treatment using EZ DNA methylation kit (Zymo Research). Briefly, 1 μg of genomic DNA was denaturated by incubating with 0.2 mol/L NaOH. Aliquots of 10 mmol/L hydroquinone and 3 mol/L sodium bisulfate (pH 5.0) were added, and the solution was incubated at 50°C for 16 hours. Treated DNA was purified, desulfonated with 0.3 mol/L NaOH, repurified on Zymo-Spin columns, and eluted with 25 μL water. MGMT promoter methylation status was analyzed by methyl-specific polymerase chain reaction (MSP). It was carried out in a 15 μL volume containing 1 μL of the sodium bisulfite-modified DNA. The characteristics of the MSP reactions and the primer sequence have been previously described (14). SW620 cell line was used as a positive control for hypermethylated alleles of MGMT and DNA from RKO cell line used as a negative control (Fig. 1).

**Figure 1.** Methyl-specific PCR for MGMT promoter. Example of results obtained for 6 metastatic colorectal cancer primary tumors from the study cohort. Tumors T2 and T7 were methylated and all the others unmethylated. U indicates unmethylated tumors and M methylated tumors. RKO was the human colorectal cancer cell line used as negative control for methylation and SW620 the human colorectal cancer cell line used as positive one. H₂O is the experiment negative control.
Statistical analysis

According to clinical considerations and on the basis of the available literature, the efficacy of a treatment in this setting of mCRC chemorefractory patients would be considered poor if the ORR is 3% or less, whereas it could be considered of clinical usefulness if the ORR is 10% or more. Assuming $\alpha = 0.05$ and $\beta = 0.20$, a Simon Optimal 2-stage design has been then chosen to test the null hypothesis that $P \leq 0.03$ versus the alternative that $P \geq 0.10$. According to this design, if at least 2 of the first 40 patients would have achieved an objective response, enrollment would have been extended by 28 patients. Overall, objective response rate of dacarbazine monotherapy would have been deemed unacceptable if objective response was 4 or less. The association between MGMT promoter methylation status and ORR and DCR was determined by 2-sided Student t-test or Fisher exact test. PFS was estimated by Kaplan–Meier product-limit method followed by log-rank test.

Results

Patients’ characteristics

Sixty-eight patients were enrolled in our institution from May 2011 until March 2012. All patients had progressed on fluoropyrimidines, oxaliplatin, irinotecan, and cetuximab or panitumumab (the latter 2 drugs if KRAS wild-type). 87% of patients had received prior bevacizumab and 19% patient had received more than 4 lines of treatment. Twenty percent of patients received mitomycin C, 4% raltitrexed, and 12% previous experimental agents within clinical trials. Clinical characteristics of patients in this trial are reported in Table 1. Reasons for discontinuation of dacarbazine treatment included hematologic toxicity (1 patient), progression (61 patients), death (4 patients), and withdrawal of consent (2 patients). Cause of death was recorded as mCRC in all deceased patients.

Toxicity

Adverse events are listed in Supplementary Table S1. Hematologic toxicity was the most frequent adverse event reported and general toxicity was consistent with the known toxicity profile of dacarbazine. We observed 3 hematologic G4 adverse events (2 platelet count decreased and one neutrophil count decreased). Hepatic failure with increased bilirubin due to progression of disease was observed in 3 patients with extensive metastatic liver involvement.

Analysis of MGMT promoter hypermethylation

Sixty-five of 68 patients were tested for MGMT promoter methylation status and ORR and DCR was determined by 2-sided Student t-tests or Fisher exact test. PFS was estimated by Kaplan–Meier product-limit method followed by log-rank test.

Table 1. Patients characteristics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Median 63.5</td>
</tr>
<tr>
<td></td>
<td>Range 29–81</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 47 (69)</td>
</tr>
<tr>
<td></td>
<td>Female 21 (31)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>No. of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance status</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>37 (54)</td>
</tr>
<tr>
<td>1</td>
<td>31 (46)</td>
</tr>
<tr>
<td>Tumor grade at diagnosis</td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>2 (3)</td>
</tr>
<tr>
<td>G2</td>
<td>43 (63)</td>
</tr>
<tr>
<td>G3</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Not available</td>
<td>14 (21)</td>
</tr>
<tr>
<td>No. of prior treatments</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>14 (21)</td>
</tr>
<tr>
<td>3</td>
<td>18 (26)</td>
</tr>
<tr>
<td>4</td>
<td>23 (35)</td>
</tr>
<tr>
<td>5</td>
<td>5 (7)</td>
</tr>
<tr>
<td>6</td>
<td>6 (9)</td>
</tr>
<tr>
<td>7</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Tumor KRAS status</td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>35 (51)</td>
</tr>
<tr>
<td>Mutated</td>
<td>33 (49)</td>
</tr>
<tr>
<td>G12V</td>
<td>7</td>
</tr>
<tr>
<td>G12C</td>
<td>5</td>
</tr>
<tr>
<td>G12S</td>
<td>1</td>
</tr>
<tr>
<td>G12D</td>
<td>7</td>
</tr>
<tr>
<td>G12A</td>
<td>1</td>
</tr>
<tr>
<td>G13D</td>
<td>5</td>
</tr>
<tr>
<td>Codon not available</td>
<td>7</td>
</tr>
<tr>
<td>Tumor MGMT methylation status</td>
<td></td>
</tr>
<tr>
<td>Hypermethylated</td>
<td>26 (38)</td>
</tr>
<tr>
<td>Unmethylated</td>
<td>39 (58)</td>
</tr>
<tr>
<td>Not assessable</td>
<td>3 (4)</td>
</tr>
<tr>
<td>No. of metastatic sites</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2 (3)</td>
</tr>
<tr>
<td>2</td>
<td>25 (37)</td>
</tr>
<tr>
<td>3</td>
<td>29 (43)</td>
</tr>
<tr>
<td>4</td>
<td>11 (16)</td>
</tr>
<tr>
<td>5</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Patients previously treated with:</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>59 (87)</td>
</tr>
<tr>
<td>Mitomycin</td>
<td>17 (25)</td>
</tr>
<tr>
<td>Experimental drugs (clinical trial)</td>
<td>8 (12)</td>
</tr>
</tbody>
</table>

Amatú et al.
and metastatic site from the same patient. In the latter case, we observed concordance in 10 of 11 pairs, with only one case showing a hypermethylated primary with unmethylated liver metastasis, and the result from liver metastasis was considered for the purpose of analysis. Sites of metastases were: liver 75% (15/20), 5% (1/20) ovary, 10% (2/20) lung, 5% (1/20) spleen, and 5% (1/20) cutaneous.

MGMT hypermethylation was more frequent (61% and 31%, respectively) in tumors carrying KRAS mutation with G > A transition (G12D, G12V, or G13D), as previously described (10, 11), although the difference was not statistically significant due to the small size (only 26 patients were evaluable for both analysis; \( P = 0.238 \)).

Antitumor activity of dacarbazine

ORR was 3%, with 2 partial responses. Stable disease was achieved in 8 of 68 patients (12%), accounting for a DCR (partial response + stable disease) of 15%. Median PFS was 57 days. Preplanned analysis of secondary endpoints based on assessments of MGMT methylation and KRAS mutation status in individual tumors showed that objective responses occurred only in patients displaying MGMT hypermethylation (Fig. 2A and Fig. 3). In addition, we observed a significantly higher DCR (44.0% vs. 6%, \( P = 0.012 \)) in the MGMT-hypermethylated group (Fig. 2). A trend toward better PFS [HR = 0.66; 95% confidence interval (CI) 0.40–1.10; \( P = 0.0982 \)] was also found in the MGMT-hypermethylated cases (Fig. 4A). A similar tendency was found between reduction of tumor volume following dacarbazine treatment and MGMT methylation status: tumor shrinkage of any size occurred more frequently in patients displaying MGMT hypermethylation (Fisher exact test, \( P = 0.093 \)). In contrast, KRAS status was not associated with PFS, DCR, and ORR (KRAS mutant vs. KRAS wild-type, \( P = 0.735, 0.999, \) and 0.492, respectively; Fig. 4B).

Discussion

In this study, we document that dacarbazine is active after failure of standard therapies only in those patients with mCRC whose tumor is harboring epigenetic inactivation of the DNA repair enzyme MGMT. Overall, we observed 2 objective responses, accounting for 3% of ORR, and 8 stable diseases, accounting for 12% of the cases. The observation of a significant association between MGMT promoter hypermethylation and these clinical endpoints supports the
hypothesis that DNA repair-defective mCRC tumors are more susceptible to this chemotherapeutic agent. However, even in the case of \textit{MGMT} hypermethylation, we observed that a fraction of 44\% of patients achieved control of disease (stable disease + partial response), thus suggesting that a multiparametric signature including the DNA methylation-associated silencing of \textit{MGMT} together with other molecular traits would improve the identification of CRC tumors with defects in DNA repair, susceptible to the action of dacarbazine.

The low response rate observed in the present cohort could be linked to the inclusion of heavily pretreated patients (median 4 lines of previous treatments). To interpret this clinical result in the context of therapy-resistant mCRC, one should consider that second-line treatment with FOLFIRI or FOLFOX combination regimens induces ORR of 10\% to 12\% \cite{24–26} and dramatically decreases in subsequent lines \cite{6}. It is also known that dacarbazine is activated in liver by CYP\textsubscript{450} microsomial N-demethylation with formation of 5-[3-hydroxymethyl-3-methyl-triazen-1-yl]-imidazole-4-carboxamide and 5-[3-methyl-triazen-1-yl]-imidazole-4-carboxamide (MTIC). Rapid decomposition of MTIC produces the major plasma and urine metabolite 5-amino-imidazole-4-carboxamide and the reactive species methane diazohydroxide, which produces molecular nitrogen and a methyl cation supposed to be the methylating species \cite{27}. It is therefore conceivable that the multiple (median 4) previous lines of cancer treatment as well as the high (79\%) rate of liver involvement in the present study population may have exhausted the liver function capacity to activate dacarbazine.

It was our hypothesis that anticancer activity of dacarbazine could be enhanced by a specific defect in DNA

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Computed tomography scan showing tumor shrinkage (white arrows) after treatment with dacarbazine in 2 patients, one with lung (A) and another with liver (B) metastases, both displaying \textit{MGMT} promoter hypermethylation in primary tumor.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{A, Kaplan–Meier PFS survival analysis according to \textit{MGMT} status in individual tumors. B, Kaplan–Meier PFS survival analysis according to \textit{KRAS} status in individual tumors.}
\end{figure}
MGMT as a Biomarker for Dacarbazine in Colorectal Cancer

repair system as evaluated by MGMT promoter hypermethylation in individual tumors. This epigenetic defect occurs in about 35% to 40% of mCRCs (9) and it is detected in more than 70% of KRAS-mutated tumors carrying the G > A transitions subtypes of mutation (10, 11), a subgroup of mCRCs with limited therapeutic options. Although the present trial was not designed, and thus, powered to assess a significant difference in PFS between MGMT-hypermethylated/unmethylated groups, we observed a trend toward better PFS in the MGMT-hypermethylated group, together with a better DCR. The 2 patients displaying objective response were indeed carrying MGMT-hypermethylated tumors (Fig. 2A) and one of them showed a long-lasting maintenance of response of 6 months, which is uncommon in the advanced setting of mCRC.

In conclusion, present data document that specific DNA repair defects can be associated with susceptibility to dacarbazine. The use of an alkylating agent that does not require hepatic activation may be preferable in heavily pretreated patients with metastatic liver disease. In this regard, temozolomide is an alkylating agent whose activity is also enhanced in tumors with MGMT loss (17) that is hydrolyzed in cells producing the active compound MTIC without requiring liver passage. A phase II trial with temozolomide has been designed and is ongoing at our institution to assess the efficacy in patients with MGMT hypermethylated mCRCs after failure of standard therapies.

Disclosure of Potential Conflicts of Interest
Andrea Sartore-Bianchi has received honoraria from speakers’ bureau from Bayer, Roche, and Amgen and is a consultant/advisory board member of Amgen. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: A. Amatu, A. Sartore-Bianchi, K. Bencardino, M. Nichelatti, S. Siena
Development of methodology: A. Amatu, A. Sartore-Bianchi, K. Bencardino, M. Esteller, S. Siena
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Amatu, A. Sartore-Bianchi, A. Belotti, K. Bencardino, A. Cassingena, F. Rusconi, S. Siena
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Amatu, A. Sartore-Bianchi, C. Moutinho, K. Bencardino, G. Chirico, A. Cassingena, F. Rusconi, M. Nichelatti, M. Esteller, S. Siena
Writing, review, and/or revision of the manuscript: A. Amatu, A. Sartore-Bianchi, C. Moutinho, K. Bencardino, M. Esteller, S. Siena
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Moutinho, A. Belotti, S. Siena
Study supervision: A. Amatu, A. Sartore-Bianchi, S. Siena
Management of data relating the clinical trial in Italian database, drug receipt: A. Esposito

Acknowledgments
The authors thank Sanofi-Aventis for donation of dacarbazine, nursing staff coordinated by chief nurses Monica Torretta (outpatients) and Elena Marino (inpatients), and to all patients and their families.

Grant Support
This work was partly supported by Oncologia Ca’ Grandi Onlus (OGCO) Fondazione, Associazione Italiana Ricerca sul Cancro (AIRC) Special Program Molecular Clinical Oncology—$5 per mille (grant no. 9970), and European Community Seventh Framework Programme under grant agreement no. 259015 COLITHERES.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 19, 2012; revised January 23, 2013; accepted February 10, 2013; published OnlineFirst February 19, 2013.

References
Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu, Andrea Sartore-Bianchi, Catia Moutinho, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-3518

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/02/18/1078-0432.CCR-12-3518.DC1

Cited articles
This article cites 25 articles, 11 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/8/2265.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/19/8/2265.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/19/8/2265.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.